Viking Therapeutics (NASDAQ:VKTX – Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.02, Briefing.com reports. During the same period last year, the business posted ($0.23) EPS.
Viking Therapeutics Stock Up 21.2 %
VKTX traded up $12.83 during trading on Thursday, hitting $73.22. The company’s stock had a trading volume of 16,322,708 shares, compared to its average volume of 4,350,632. The stock has a market capitalization of $8.07 billion, a price-to-earnings ratio of -78.73 and a beta of 1.00. Viking Therapeutics has a 12 month low of $8.28 and a 12 month high of $99.41. The firm’s 50 day moving average price is $62.92 and its two-hundred day moving average price is $61.66.
Insider Transactions at Viking Therapeutics
In other news, CEO Brian Lian sold 216,130 shares of the business’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $70.83, for a total transaction of $15,308,487.90. Following the completion of the sale, the chief executive officer now owns 2,304,927 shares in the company, valued at $163,257,979.41. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director J Matthew Singleton sold 20,786 shares of the business’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.53, for a total transaction of $1,195,818.58. Following the completion of the sale, the director now owns 9,500 shares in the company, valued at $546,535. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Brian Lian sold 216,130 shares of Viking Therapeutics stock in a transaction on Friday, September 20th. The stock was sold at an average price of $70.83, for a total value of $15,308,487.90. Following the sale, the chief executive officer now directly owns 2,304,927 shares of the company’s stock, valued at approximately $163,257,979.41. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 516,671 shares of company stock worth $33,810,813 over the last 90 days. 4.70% of the stock is owned by insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on Viking Therapeutics
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories
- Five stocks we like better than Viking Therapeutics
- What Investors Need to Know About Upcoming IPOs
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Manufacturing Stocks Investing
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Calculate Options Profits
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.